Abstract
Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in platinum-pretreated non-small-cell lung cancer (NSCLC).
This randomized, double-blind, multicenter, phase II trial evaluated sunitinib 37.5 mg/day plus erlotinib 150 mg/day versus placebo plus erlotinib continuously in 4-week cycles. Eligible patients had histologically confirmed stage IIIB or IV NSCLC previously treated with one or two chemotherapy regimens, including one platinum-based regimen. The primary end point was progression-free survival (PFS) by an independent central review.
One hundred and thirty-two patients were randomly assigned, and the median duration of follow-up was 17.7 months. The median PFS was 2.8 versus 2.0 months for the combination versus erlotinib alone (HR 0.898, P = 0.321). The median overall survival (OS) was 8.2 versus 7.6 months (HR 1.066, P = 0.617). Objective response rates (ORRs) were 4.6% and 3.0%, respectively. Sunitinib plus erlotinib was fairly well tolerated although most treatment-related adverse events (AEs) were more frequent than with erlotinib alone: diarrhea (55% versus 33%), rash (41% versus 30%), fatigue (31% versus 25%), decreased appetite (30% versus 13%), nausea (28% versus 14%), and thrombocytopenia (13% versus 0%).
The addition of sunitinib to erlotinib did not significantly improve PFS in patients with advanced, platinum-pretreated NSCLC.
Original language | English |
---|---|
Pages (from-to) | 2382-2389 |
Number of pages | 8 |
Journal | Annals of Oncology |
Volume | 24 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sept-2013 |
Keywords
- combination therapy
- efficacy
- erlotinib
- non-small-cell lung cancer
- safety
- sunitinib
- TYROSINE KINASE INHIBITOR
- ENDOTHELIAL GROWTH-FACTOR
- PLUS ERLOTINIB
- ANTITUMOR-ACTIVITY
- IN-VIVO
- TRIAL
- SU11248
- BEVACIZUMAB
- CHEMOTHERAPY
- CARCINOMA